N. Reed

Uterine sarcoma subtypes and their differentiation from non-sarcomatous entities using MRI.

D. Millan, G. Cassels, F. Bryden, 2014 .

VERSUS UPFRONT DEBULKING SURGERY IN ADVANCED TUBO-OVARIAN

G. Jayson, G. Kenter, M. Nankivell, 2018 .

Rare and uncommon gynecological cancers

D. Gershenson, N. Siddiqui, John A. Green, 2011 .

Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).

M. Gore, J. Ledermann, G. Rustin, 2015 .

Malignant struma ovarii: The west of Scotland experience and review of literature with focus on postoperative management

N. Reed, R. Shrimali, G. Shaikh, 2012, Journal of medical imaging and radiation oncology.

LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

A. Colao, J. Metges, R. García-Carbonero, 2022, Annals of Oncology.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

M. Dietel, W. Travis, H. Moch, 2018, Modern Pathology.

ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

E. Krenning, F. Keleştimur, M. Pavel, 2016, Neuroendocrinology.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Castiglione, R. Verheijen, N. Reed, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of neuroendocrine tumours.

N. Reed, N. Reed, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).